GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC). According to GlobalData, Phase I drugs for Head And Neck Squamous Cell Carcinoma (HNSC) have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GH-21’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GH-21 overview
GH-21 is under development for the treatment of colorectal cancer, head and neck squamous cell carcinoma (HNSCS), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumor. The drug candidate is administered through oral route. It is a small molecule which acts by targeting SHP2.
HUYA Bioscience International overview
HUYA Bioscience International (HUYA) is a biopharmaceutical company that develops novel oncology and cardiology therapy products. The company’s oncological pipeline products include HBI-8000, HBI-2376 and HBI-ONC. Its HBI-8000, treat 2L lung cancer, 1L melanoma, peripheral T-cell lymphoma and adult T- cell leukemia; HBI-2376, treats solid tumors and HBI-ONC, treats myelodysplastic syndrome and acute myeloid leukemia. HUYA’s cardiology products HBI-3000 and HBI-3800 treat atrial fibrillation and post-myocardial infarction. The company works in collaboration with biopharmaceutical, academic and commercial organizations. It operates in the US, China, South Korea, Japan, Canada and Ireland. HUYA is headquartered in San Diego, California, the US.
For a complete picture of GH-21’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
